Corrigendum: Dynamics of Emergency Cardiovascular Hospital Admissions and In-Hospital Mortality During the COVID-19 Pandemic: Time Series Analysis and Impact of Socioeconomic Factors
- 1Cardiovascular Research and Epidemiology Unit, Cardiology Department, University Hospital Vall d’Hebron and Vall d’Hebron Research Institute, Barcelona, Spain
- 2Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- 3Recerca en Envelliment, Fragilitat i Transicions (REFiT) Barcelona Research Group, Parc Sanitari Pere Virgili and Vall d’Hebron Institute of Research, Barcelona, Spain
- 4Cardiology Department, Hospital Universitari de Bellvitge, Barcelona, Spain
- 5Bioheart, Grup de Malalties Cardiovasculars, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
- 6Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
- 7Statistics and Bioinformatics Unit, Vall d’Hebron Research Institute, Barcelona, Spain
- 8Statistics Department, Faculty of Biology, University of Barcelona, Barcelona, Spain
- 9Cardiology Department, University Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
- 10Clinical Epidemiology Unit, Hospital Universitario Cruces/BioCruces-Bizkaia Health Research Institute, Barakaldo, Spain
- 11Cardiology Department, Hospital German Trias i Pujol, Barcelona, Spain
- 12Director Plan for Cardiovascular Diseases, Pla Director de Malalties Cardiovasculars (PDMCV), Department of Health, Catalan Government, Barcelona, Spain
Aims: This study aimed to evaluate the decline in urgent cardiovascular hospital admissions and in-hospital mortality during the COVID pandemic in two successive waves, and to evaluate differences by sex, age, and deprivation index subgroups.
Methods and Results: We obtained acute cardiovascular hospital episodes during the years 2019–2020 from region-wide data on public healthcare usage for the population of Catalonia (North-East Spain). We fitted time models to estimate the incidence rate ratios (IRRs) of the acute coronary syndrome (ACS) and acute heart failure (HF) admissions during the first pandemic wave, the between-waves period, and the second wave compared with the corresponding pre-COVID-19 periods and to test for the interaction with sex, age, and area-based socioeconomic level. We evaluated the effect of COVID-19 period on in-hospital mortality. ACS (n = 8,636) and HF (n = 27,566) episodes were defined using primary diagnostic ICD-10 codes. ACS and HF admissions decreased during the first wave (IRR = 0.66, 95%CI: 0.58–0.76 and IRR = 0.61, 95% CI: 0.55–0.68, respectively) and during the second wave (IRR = 0.80, 95%CI: 0.72–0.88 and IRR = 0.76, 95%CI: 0.69–0.84, respectively); acute HF admissions also decreased in the period between waves (IRR: 0.81, 95%CI: 0.74–0.89). The impact was similar in all sex and socioeconomic subgroups and was higher in older patients with ACS. In-hospital mortality was higher than expected only during the first wave.
Conclusion: During the first wave of the COVID-19 pandemic, there was a marked decline in urgent cardiovascular hospital admissions that were attenuated during the second wave. Both the decline and the attenuation of the effect have been similar in all subgroups regardless of age, sex, or socioeconomic status. In-hospital mortality for ACS and HF episodes increased during the first wave, but not during the second wave.
Introduction
During the first pandemic wave (FW) of coronavirus disease 2019 (COVID-19) between March and April 2020, there was a marked decline in admissions for acute coronary syndrome (ACS) (1–11), heart failure (HF) (12–14), and other non-COVID health conditions (15–17).
While prioritization of healthcare services explains decreases in elective admissions, explanations for the decrease in the attention of emergent conditions remain conjectural (18). Possible reasons attributed to the steep decrease in hospital admissions for acute cardiovascular problems were patients’ hesitation to refer to the hospital, missed diagnosis, and competing risk with COVID-19 mortality in the elderly and institutionalized patients (19). The analysis of differing trends of emergent cardiovascular admissions in successive waves periods and in the between-waves periods (BWP) might be useful to unravel the underlying mechanisms and to anticipate future trends. A few reports of results during the second pandemic wave (SW, between April and September 2020) indicate a second decline of unknown magnitude (20) despite information campaigns targeted at the affected populations.
Moreover, the COVID-19 pandemic has been shown to increase geographic, gender, and socioeconomic inequalities in access to healthcare (21). Age, gender, and deprivation level might influence behaviors in such ways that would imply a greater impact on more disadvantaged groups. Gender and age differences in admissions for acute myocardial infarction (MI) have been analyzed previously with differing results (22); but to the best of our knowledge, it has not been assessed in longer series (beyond the FW) considering socioeconomic indices. The potential influence of gender, age, and socioeconomic differences on the dynamic of admissions for acute HF decompensations has not been assessed so far.
Therefore, we aimed to evaluate the variations in ACS and acute HF hospital admissions during the COVID-19 pandemic period, including the FW and the SW, in comparison with the hospital admissions of the corresponding pre-COVID-19 pandemic periods. In addition, we aimed to assess whether age, gender, and socioeconomic status might have influenced these variations. Finally, we analyzed the predictors of in-hospital death.
Materials and Methods
Population and Data Sources
We used region-wide data on public healthcare usage for the population of Catalonia, a North-East region in Spain with universal public healthcare coverage, with a reference population of more than 7 M and a hospital network of 11 reference tertiary hospitals performing percutaneous coronary intervention (PCI). Data were accessed through the Public Data Analysis for Health Research and Innovation Program (PADRIS). PADRIS allows access to information from different sources linked at the patient level with warranted accomplishment of ethical principles and the Spanish Law of data protection 3/2018.
Acute coronary syndrome and HF episodes from 31 December 2018 to 27 December 2020 were extracted from the Minimum Basic Data Set (MBD). Index admissions were identified with the International Classification of Diseases (ICD)-10 as the primary diagnostic (see diagnostic codes in Supplementary Table 1). We selected only emergency admissions.
Weekly COVID-19 cases were obtained from the Open Access Data Portal of the Catalan Government. Confirmed cases were defined as having a positive RT-PCR test or rapid antigen test for SARS-CoV-2.
For each episode, we extracted sex, age in 5 years’ intervals, all diagnostic and procedure ICD-10 codes, region of residence, primary care service areas (PCSA), comorbidity status (AMG), and PCSA-based socioeconomic status (PCSA index).
Primary Care Service Areas Index
To strengthen territorial equity in the allocation of primary care resources, in 2015, the Catalan Health Department developed a socioeconomic deprivation indicator representative of the PCSA linked to adverse health outcomes. The indicator score ranges from 0 (less deprived) to 100 (more deprived) (23).
Comorbidity
The comorbidity index [Adjusted Morbidity Groups (AMGs)] score is a morbidity measure that enables assigning a weight based on the preexisting comorbidities (24). AMG explanatory value has been checked by comparing it with morbidity measures such as the Charlson Index or the number of chronic diseases (24).
Statistical Analysis
Based on the visual representation of the weekly number of COVID-19 diagnostics, we defined the following periods of analysis: pre-COVID (from 31 December 2018 to 23 February 2020), FW (from 24 February 2020 to 27 April 2020), BWP (from 28 April 2020 to 20 September 2020), and SW (from 21 September 2020 to 27 December 2020). We considered the beginning of the FW as the date when the first case in the region was reported in the press (24 February 2020), although the COVID registry started later.
Patients’ characteristics were compared between each COVID period and the corresponding pre-COVID period (same calendar period in 2019). Continuous variables were reported as mean (SD) or median (P25 to P75) and compared using Student’s t-tests or Kruskal-Wallis tests. Categorical variables were reported as n (percentage) and compared using χ2 tests.
Weekly admissions for ACS and HF were depicted from 31 December 2018 to 27 December 2020. Negative binomial regression was used to estimate the incidence rate ratios (IRRs) and their 95% confidence intervals for ACS and acute HF hospital admissions during the COVID-19 FW, during the BWP, and during the SW compared with the expected admissions, based on the pre-COVID-19 period. Using this approach, each IRR represents the ratio between the weekly number of admissions in each period and the weekly number of admissions in the reference period. First, we modeled the pre-COVID-19 time series to estimate the expected number of admissions in the COVID-19 periods by fitting sinusoidal functions to control seasonality and autocorrelation. Best-fitted models were selected on the basis of minimizing deviance of the model and then fitted to the whole series including COVID waves as indicators to calculate IRR. To show graphically the variations in ACS and HF hospital admissions attributable to the pandemic phases, we depicted the observed vs. the expected admissions estimated from the pre-COVID-19 model.
Finally, we fitted an additional set of models using fractional polynomial coefficients to parameterize in a flexible way the different descending and ascending slopes observed during the pandemic period. We used the parameters of the fitted models to estimate the instantaneous rate of change in the different periods and the absolute decrease in each wave.
Different effects of COVID periods [FW, BWP, and SW among sex, age (<80/≥80), and PCSA index quartiles (first quartile/fourth quartile)] were estimated by including two-way interaction terms in regression models.
To assess whether changes in hospital mortality during the COVID-19 period were due to the distortion in healthcare during the pandemic or to changes in the risk profile of patients, we performed logistic mixed-effects regression with in-hospital mortality as the response variable and the pandemic periods together as a covariable. We adjusted the model by patients’ characteristics [e.g., sex, age, comorbidity weight, type of ACS (in ACS model), PCSA index quartiles]. We used random slope models and non-structured covariance matrix for random effects to account for repeated episodes of individual patients and for the clustered structure of patients living in different PCSA (371 PCSA). All analyses were performed with R version 4.1.0.
Results
After excluding elective admissions and patients younger than 20 years old, we analyzed a series of 36,202 episodes (corresponding to 34,575 patients) admitted for ACS (n = 8,424) or HF (26,151) between 31 December 2018 and 27 December 2020 (Figure 1).
Tables 1, 2 show the characteristics of patients attended for ACS and HF during each predefined COVID-19 period as compared with each corresponding pre-COVID-19 period: FW, BWP, and SW. The decline in admissions for every subgroup is presented as a% change. The description of the complete cohort is shown in Supplementary Table 2.
Table 1. Characteristics of patients admitted to hospital for acute coronary syndrome (ACS) in each period compared with the reference pre-COVID-19 period.
Table 2. Characteristics of patients admitted to hospital for acute heart failure (HF) in each period compared with the reference pre-COVID-19 period.
In general, patients admitted during the pandemic period had less comorbidities, as reflected by a consistently lower AMG score compared with the pre-COVID periods. In addition, in both conditions, the total hospital length of stay was significantly lower. Regarding ACS admissions (Table 1), the decline was significantly higher for patients aged 80 years or older admitted during the SW. Diagnostic episodes labeled as other AMI or other ACS increased in the whole COVID-19 period. As compared with the pre-COVID-19 period, the number of PCI remained virtually the same during the FW but decreased slightly during the BWP (−23%; p = 0.001) and during the SW (−32%; p = 0.01). In-hospital mortality increased during the FW [8.86% vs. 5.51% in the pre-COVID-19 period (p = 0.018)], and there were no statistically significant differences neither during the SW nor in the BWP.
Regarding acute HF admissions (Table 2), the proportion of older people admitted during the BWP was significantly lower, and in-hospital mortality was higher during the FW (7.41 vs. 9.26%; p = 0.022) but lower during the BWP (7.46 vs. 6.38%; p = 0.039) and during the SW (7.63% vs. 5.94%; p = 0.007).
Figure 2 shows the time series of ACS (Figure 2A) and HF (Figure 2B) weekly urgent hospital admissions and the distortion observed after the arrival of the pandemic wave. Both ACS and HF admissions series showed a significant seasonality, with lower admissions in summer weeks. After adjusting for seasonality and autocorrelation, there was a marked decrease in ACS episodes (Supplementary Figure 1A), reaching a maximum of 69.46% cases below the expected [IRR 0.43 (0.37–0.50), p < 0.001] coinciding with the highest peak of the FW. Then, after a recovery in the BWP, the number of admissions decreased again in a smoother way. Admissions for HF (Supplementary Figure 1B) also decreased steeply to a 72.83% less than expected [IRR 0.21 (0.17–0.26), p < 0.001] coinciding with the peak of the FW and then returned to normal levels to immediately decrease again to a sustained level about 30% below the expected.
Figure 2. Weekly number of hospital admissions for (A) acute coronary syndrome and (B) heart failure, between 31 December 2018 and 27 December 2020. Black line: observed hospital admissions; shaded area: number of COVID-19 cases; red lines: predefined period limits: pre-pandemic, first wave, period between waves, and second wave; small circles: negative binomial model estimated values (pre-COVID-19).
The model parameters used to estimate IRRs and changes in the weekly number of admissions are shown in Supplementary Tables 3–6. The IRRs of ACS admissions for the FW, the BWP, and the SW were 0.66 (0.58–0.76), 0.92 (0.84–1.00), and 0.80 (0.72–0.88), respectively. The IRRs of HF admissions for the FW, the BWP, and the SW were 0.61 (0.55–0.68), 0.81 (0.74–0.89), and 0.76 (0.69–0.84), respectively. Supplementary Figures 2, 3 show the results of the models with fractional polynomic coefficients for ACS and HF.
Supplementary Figures 4–15 show the separate time series according to gender, age, and area-level deprivation index. For the IRRs of ACS admissions, there was a significant interaction with age in the BWP and in the SW (Figure 3), when the relative reduction in the weekly number of admissions was higher for older people. Despite an apparent recovery in the admissions for ACS in the BWP [IRR 0.92 (0.84–1.00)], ACS admissions remained lower than expected among women, older, and in most deprived areas. Regarding HF, there was a significant decline of a similar magnitude in all subgroups (Figure 4), and HF admissions remained significantly lower than expected during the whole pandemic period.
Figure 3. Incidence rate ratios of acute coronary syndrome admissions, in the three predefined pandemic period vs. the corresponding pre-pandemic period (2019) by subgroups of socioeconomic factors, and the p-value for the interaction between period and each socioeconomic factor.
Figure 4. Incidence rate ratios of acute heart failure admissions, in the three predefined pandemic period vs. the corresponding pre-pandemic period (2019) by subgroups of socioeconomic factors, and the p-value for the interaction between period and each socioeconomic factor.
Table 3 shows the association between the COVID-19 epidemic periods and in-hospital mortality adjusted for patient demographics, AMG score, type of ACS, and PCSA index. Mortality risk, compared with the corresponding pre-COVID-19 periods, was higher during the FW for both ACS (OR: 2.29; 95%CI: 1.6–3.27; p < 0.001) and HF episodes (OR: 1.33; 95% CI: 1.11–1.59; p = 0.002). In addition, ACS episodes labeled as other MI had the highest mortality risk (8.9; 95% CI 5.44–14.58; p < 0.001) as well as those episodes with a concomitant or recent diagnosis of coronavirus infection (OR: 4.1; 95% CI: 1.78–9.44; p = 0.001 and OR: 1.87; 95% CI: 1.22–2.86; p = 0.004 for ACS and HF, respectively).
Table 3. Association of patient characteristics and COVID-19 periods with in-hospital mortality for acute coronary syndrome (ACS) and heart failure (HF).
Discussion
This population-based time-trends analysis shows an important decrease in the number of emergent admissions for ACS and HF during the FW and during the SW compared with the corresponding pre-COVID-19 periods. This decrease was also present during the BWP, and it was similar among socioeconomic subgroups. However, there were less patients aged 80 years or older admitted for ACS during the BWP and the SW. Adjusted in-hospital mortality risk compared with the corresponding pre-COVID-19 periods was higher during the FW for both ACS and HF episodes despite a lower comorbidity weight and a similar rate of PCI.
Although the decrease in cardiovascular admissions was consistent during all the study periods, the impact of the SW was clearly different from the impact of the FW. The impact of the SW was quite attenuated, probably due to the rapid reaction of hospitals to increase their intensive care capacity and to the information campaigns launched to raise awareness of the need to contact the emergency services when experiencing symptoms compatible with MI.
There were also remarkable differences between ACS episodes and acute HF episodes. While the number of ACS admissions gradually returned to the expected levels in the BWP, admissions for acute HF remained low for almost the whole observed pandemic period studied. Whether the number of admissions has recovered to usual values or has decreased again to similar levels in the successive waves needs to be further addressed. Besides patients’ hesitation to go to the hospital, this sustained decrease might be related in part to the fact that HF symptoms are closer to COVID-19 symptoms. Since the primary focus of health professionals has been a rapid COVID-19 diagnosis, it might have led to underdiagnoses of HF cases. In addition, acute HF hospitalizations might have been lower because patients were preferably attended to in the primary care setting or due to the increased use of telemedicine, which is less practicable in the setting of the acute ischemic heart disease.
It has been speculated that lifestyle changes occurring during the lockdown periods might have influenced acute coronary disease incidence (25). However, the observations, as in other contexts (8), that the decline in admissions preceded the lockdown and that the return to “normal” levels preceded the reopening suggest that environmental changes, decreased physical activity, or diminished stress are unlikely to be major contributors to these trends.
Some changes in the characteristics of patients attended to during the successive COVID-19 periods compared with the corresponding pre-COVID-19 periods might give some hints for the interpretation of trends. Overall, patients admitted during the COVID-19 period had much lower comorbidity weight assessed by AMG score. This suggests that those patients with more comorbidities and higher risk who had a cardiovascular event did not seek care or that the healthcare system collapsed at some point and could not hospitalize these more fragile patients. Another possibility is a certain degree of competitive risk between COVID-19 disease and cardiovascular events, which could result in a lower rate of cardiovascular events in the population with a higher rate of severe COVID-19 disease, which was precisely the elderly and the more fragile population, especially during the FW. The stronger decrease in admissions of patients aged 80 years or older in the BWP and during the SW supports the hypothesis of competitive risk with the high COVID-19-related mortality during the FW.
Another indirect finding that suggests the burden of the healthcare facilities during certain periods was the hospital length of stay. It declined steadily during the epidemic waves and, to a lesser extent, during the BWP. In the future, it will become clear whether this indicates a simple trend in a complex context or a real change in the efficiency of the health system for managing these cardiovascular events. In any case, it indicates the effort of the healthcare professionals to minimize the overload of the system and the awareness of the risk of infection during admission by professionals and by the patients and their families.
The increase in the number of diagnoses labeled as other ACS or other MI, present in only few cases, might be due to codification problems during the overwhelming working conditions of the professionals responsible for codification during the pandemic peaks. This fact prevents us to draw conclusions about the differential changes by type of ACS.
The analysis of mortality determinants reveals that, unlike the results observed in other series (26), there was a significantly increased risk of in-hospital mortality after ACS and acute HF episodes in the FW but not in the SW. The increase in mortality was independent of case mix and despite a lower comorbidity weight and a similar rate of PCI compared with the pre-COVID-19 period. This probably reflects, on the one hand, the delay in patients seeking care increasing symptoms-to-balloon time (2), together with a more important healthcare overload during the FW and, on the other hand, a certain learning curve effect that benefited the second and subsequent waves.
Our results are consistent with those observed in other contexts. The study by Bodilsen et al. (16), in Denmark, highlighted HF as one of the health conditions not returning to baseline levels, together with respiratory and nervous system diseases, cancer, acute exacerbations of chronic pulmonary disease, sepsis, and pneumonia.
Although female sex and older age have been linked to increased delay before seeking healthcare (27), the COVID-19 pandemic does not seem to have affected differently the pattern of admission for ACS and HF in male and female patients (Figures 3, 4). This suggests that the potential different behavior of men and women for seeking care shown in other studies is attenuated in a context such as COVID-19 pandemic. However, we observed that the decline in hospital admissions was higher in older patients, but only after the FW. Huynh et al. (28) found a higher reduction of acute MI in women ≥70 years old during the COVID-19 pandemic in a Swedish healthcare region without lockdown.
To the best of our knowledge, this is the largest study showing the effects of the COVID-19 pandemic on acute cardiovascular disease admissions during a sufficiently large time window to include two successive waves. Previous reports have observed lower hospital admission rates for MI (5, 6, 11, 29, 30) and HF (13, 14, 31, 32) during the FW that are comparable with our study; however, reports of further declines in successive waves are scarce. In this sense, Wu et al. (20) reported a second decline of a similar magnitude (41% for HF and 34% for MI) during the SW in the United Kingdom.
Limitations
Despite the use of large region-wide administrative databases that offer clear advantages, disadvantages include the following: Lack of detail in clinical severity, comorbidities, out-of-hospital mortality and causes of mortality, lower data quality, and higher risk of misclassification. In the case of HF, it would have been informative to merge hospital admissions to primary care emergent admissions and telecare attentions. Adoption of telecare programs as a response to the pandemic might have influenced the rate of hospital admissions. Finally, we used related ICD-10 diagnostic codes to label cases with concomitant COVID-19, as we did not have access to data for laboratory-proven SARS-Cov-2 infection. However, the proportion of patients with a diagnosis of both cardiovascular disease and COVID-19 infection was low, and its impact on overall outcomes might not be very relevant. Finally, the depiction of the COVID wave does not correspond with the real cases, especially during the FW, when fewer RT-PCR tests or rapid antigen tests for SARS-CoV-2 were performed, and specific diagnostic codes for COVID-19 were not available.
Conclusion and Practical Implications
The decline in hospital admissions for ACS and acute HF during the FW of the COVID-19 pandemic was marked and striking. We provide evidence that the decline was attenuated but still observed in the SW and that the impact has been similar in all age, sex, and socioeconomic subgroups in the Catalan healthcare system. In addition, the adjusted in-hospital mortality risk comparing the corresponding pre-COVID-19 periods shows a clearly higher risk during the FW for both ACS and HF episodes but not during the SW, which indicates the difficulty of the healthcare system to adapt to new and stressful pandemic conditions.
The impact of COVID-19 in Spain was among the strongest reported worldwide, and its indirect impact on other non-COVID health conditions should be surveilled by health authorities. Numerous efforts have been made to forecast health resources needs for COVID-19 but not for other health problems that have been strongly impacted by the pandemic. Extending our temporal series to longer time frames, and including other contextual factors that might influence the rate of ACS or HF admissions, can serve to anticipate future distortions and prepare the health services to improve the attention of non-COVID health problems.
Data Availability Statement
The data analyzed in this study is subject to the following licenses/restrictions: Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors upon request with the permission of AQuAS. Requests to access these datasets should be directed to https://aquas.gencat.cat/ca/ambits/analitica-dades/padris/.
Ethics Statement
The studies involving human participants were reviewed and approved by Clinical Research Ethics Committee Vall d’Hebron. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author Contributions
AR, AA-S, and IF-G conceived the study. AR received funds for the study. AR, JM, RL, and CÁ-M obtained the data. AR, CÁ-M, JRM, and SP-H performed the data management and statistical analysis. AR and IF-G have drafted the manuscript. All authors participated in the study design, contributed to the interpretation of the results, revised it critically for important intellectual content, and gave the final approval.
Funding
This study was funded with a grant from Sociedad Española de Cardiología y Fundación Española del Corazón (SEC/FEC-INV-CLI 21/017). The funder had no role in the study development.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
This study was carried out using anonymized data provided by the Agency for Health Quality and Assessment of Catalonia (AQuAS), within the framework of the Public Data Analysis for Health Research and Innovation Program (PADRIS).
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.827212/full#supplementary-material
References
1. Romaguera R, Ribera A, Güell-Viaplana F, Tomás-Querol C, Muñoz-Camacho JF, Agudelo V. Decrease in ST-segment elevation myocardial infarction admissions in Catalonia during the COVID-19 pandemic. Rev Esp Cardiol. (2020) 73:778–80. doi: 10.1016/j.rec.2020.06.001
2. Rodríguez-Leor O, Cid-Álvarez B, Pérez de Prado A, Rossello X, Ojeda S, Serrador A, et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Rev Esp Cardiol. (2020) 73:994–1002.
3. Mesnier J, Cottin Y, Coste P, Ferrari E, Schiele F, Lemesle G, et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health. (2020) 5:536–42. doi: 10.1016/S2468-2667(20)30188-2
4. Tam CCF, Cheung KS, Lam S, Wong A, Yung A, Sze M, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. (2020) 13:e006631. doi: 10.1161/CIRCOUTCOMES.120.006631
5. De Filippo O, D’Ascenzo F, Angelini F, Bocchino PP, Conrotto F, Saglietto A, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. (2020) 383:88–9. doi: 10.1056/NEJMc2009166
6. Garcia S, Albaghdadi M, Meraj P, Schmidt C, Garberich R, Jaffer FA, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. (2020) 75:2871–2. doi: 10.1016/j.jacc.2020.04.011
7. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess deaths from covid-19 and other causes, March-April 2020. JAMA. (2020) 324:510–3. doi: 10.1001/jama.2020.11787
8. Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. (2020) 396:381–9. doi: 10.1016/S0140-6736(20)31356-8
9. Gluckman TJ, Wilson MA, Chiu ST, Penny BW, Chepuri VB, Waggoner JW, et al. Case rates, treatment approaches, and outcomes in acute myocardial infarction during the coronavirus disease 2019 pandemic. JAMA Cardiol. (2020) 5:1419–24. doi: 10.1001/jamacardio.2020.3629
10. Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J. (2020) 41:1852–3. doi: 10.1093/eurheartj/ehaa314
11. Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung SH, et al. The covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. (2020) 383:691–3.
12. Reza N, DeFilippis EM, Jessup M. Secondary impact of the COVID-19 pandemic on patients with heart failure. Circ Heart Fail. (2020) 13:e007219. doi: 10.1161/CIRCHEARTFAILURE.120.007219
13. König S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A, et al. In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network. Eur J Heart Fail. (2020) 22:2190–201. doi: 10.1002/ejhf.2044
14. Shoaib A, Van Spall HGC, Wu J, Cleland JGF, McDonagh TA, Rashid M, et al. Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. Eur Hear J Qual Care Clin Outcomes. (2021) 7:378–87. doi: 10.1093/ehjqcco/qcab040
15. Rosenbaum L. The untold toll - the pandemic’s effects on patients without Covid-19. N Engl J Med. (2020) 382:2368–71. doi: 10.1056/NEJMms2009984
16. Bodilsen J, Nielsen PB, Søgaard M, Dalager-Pedersen M, Speiser LOZ, Yndigegn T, et al. Hospital admission and mortality rates for non-covid diseases in Denmark during covid-19 pandemic: nationwide population based cohort study. BMJ. (2021) 373:n1135. doi: 10.1136/BMJ.N1135
17. Ullrich A, Schranz M, Rexroth U, Hamouda O, Schaade L, Diercke M, et al. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: an analysis of national surveillance data during week 1–2016 – week 32–2020. Lancet Reg Health Eur. (2021) 6:100103. doi: 10.1016/j.lanepe.2021.100103
18. Mercier G, Arquizan C, Roubille F. Understanding the effects of COVID-19 on health care and systems. Lancet Public Health. (2020) 5:e524. doi: 10.1016/S2468-2667(20)30213-9
19. Cameli M, Pastore MC, Mandoli GE, D’Ascenzi F, Focardi M, Biagioni G, et al. COVID-19 and acute coronary syndromes: current data and future implications. Front Cardiovasc Med. (2021) 7:593496. doi: 10.3389/fcvm.2020.593496
20. Wu J, Mamas MA, de Belder MA, Deanfield JE, Gale CP. Second decline in admissions with heart failure and myocardial infarction during the COVID-19 pandemic. J Am Coll Cardiol. (2021) 77:1141–3. doi: 10.1016/j.jacc.2020.12.039
21. Abrams E, Szefler S. COVID-19 and the impact of social determinants of health. Lancet Respir Med. (2020) 8:659–61. doi: 10.1016/S2213-2600(20)30234-4
22. Moreno R, Alonso JJ, Caballero R, Del Corral E, Elízaga J, Asenjo RM, et al. Age and gender influence on time of arrival for STEMI patients during Covid-19 pandemic. Am J Emerg Med. (2021) 42:244–5. doi: 10.1016/j.ajem.2020.06.013
23. Colls C, Mias M, García-Altés A. Un índice de privación para reformar el modelo de financiación de la atención primaria en Cataluña. Gac Sanit. (2020) 4:44–50. doi: 10.1016/j.gaceta.2018.07.015
24. Monterde D, Vela E, Clèries M. Adjusted morbidity groups: a new multiple morbidity measurement of use in Primary Care. Aten Primaria. (2016) 48:674–82. doi: 10.1016/j.aprim.2016.06.003
25. Tsigkas G, Koufou EE, Katsanos K, Patrinos P, Moulias A, Miliordos I, et al. Potential relationship between lifestyle changes and incidence of hospital admissions for acute coronary syndrome during the covid-19 lockdown. Front Cardiovasc Med. (2021) 8:604374. doi: 10.3389/fcvm.2021.604374
26. Scalise M, Bossone E, Mannelli MP, Ranieri B, Franzese M, Castaldo R, et al. STEMI-PCI incidence rates and outcomes during COVID-19 pandemic: insights from Cardarelli Hospital, Naples, Southern Italy. Eur J Prev Cardiol. (2021). [Online ahead of print]. doi: 10.1093/EURJPC/ZWAB165
27. Moser DK, McKinley S, Dracup K, Chung ML. Gender differences in reasons patients delay in seeking treatment for acute myocardial infarction symptoms. Patient Educ Couns. (2005) 56:45–54. doi: 10.1016/j.pec.2003.11.011
28. Huynh J, Barmano N, Karlsson J-E, Stomby A. Sex and age differences in the incidence of acute myocardial infarction during the COVID-19 pandemic in a Swedish health-care region without lockdown: a retrospective cohort study. Lancet Healthy Longev. (2021) 2:e283–9. doi: 10.1016/s2666-7568(21)00085-4
29. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. (2020) 41:2083–8.
30. Campo G, Fortuna D, Berti E, De Palma R, Di Pasquale G, Galvani M, et al. In- and out-of-hospital mortality for myocardial infarction during the first wave of the COVID-19 pandemic in Emilia-Romagna, Italy: a population-based observational study. Lancet Reg Health Eur. (2021) 3:100055. doi: 10.1016/j.lanepe.2021.100055
31. Blecker S, Jones SA, Petrilli CM, Admon AJ, Weerahandi H, Francois F, et al. Hospitalizations for chronic disease and acute conditions in the time of COVID-19. JAMA Intern Med. (2021) 181:269–71. doi: 10.1001/jamainternmed.2020.3978
Keywords: COVID-19, acute coronary syndrome, myocardial infarction, heart failure, time-series
Citation: Álvarez-Martín C, Ribera A, Marsal JR, Ariza-Solé A, Pérez-Hoyos S, Oristrell G, Soriano-Colomé T, Romaguera R, Pijoan JI, Lidón RM, Mauri J and Ferreira-González I (2022) Dynamics of Emergency Cardiovascular Hospital Admissions and In-Hospital Mortality During the COVID-19 Pandemic: Time Series Analysis and Impact of Socioeconomic Factors. Front. Cardiovasc. Med. 9:827212. doi: 10.3389/fcvm.2022.827212
Received: 01 December 2021; Accepted: 24 March 2022;
Published: 26 April 2022.
Edited by:
Jose R. Medina Inojosa, Mayo Clinic, United StatesReviewed by:
Mubashir Ayaz Ahmed, AMITA Health St Joseph Hospital, United StatesMaria Irene Barillas Lara, Boston Medical Center, United States
Copyright © 2022 Álvarez-Martín, Ribera, Marsal, Ariza-Solé, Pérez-Hoyos, Oristrell, Soriano-Colomé, Romaguera, Pijoan, Lidón, Mauri and Ferreira-González. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Aida Ribera, YXJpYmVyYXNAcGVyZXZpcmdpbGkuY2F0